Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Feb 24 | 2023Breyanzi Absent from February’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19, TCR Feb 24 | 2023Clinical Results from P-MUC1C-ALLO1 and P-BCMA-ALLO1; Novel Allogeneic CAR-T (P-ckit-ALLO1) for AML; Upcoming Milestones for Poseida; Poseida’s R&D Day SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Feb 20 | 2023Christi Shaw to Depart Gilead and Kite LeadershipAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 20 | 2023Type II Variation for Breyanzi Listed in February’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 14 | 2023Topline Results from Abecma's KarMMa-3 in ≥3L MM; BMS, Gilead (Kite), and Novartis Present Clinical Updates from Leading CAR-T Assets; EBMT - EHA CAR-T Meeting 2023 Analysis 2Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 13 | 2023Cellpoint (Galapagos) and Takeda Present Novel CAR-Ts for Hematological Tumors; EBMT - EHA CAR-T Meeting 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 03 | 2023Gilead Reports Strong Cell Therapy Revenues; ZUMA-23 Delayed? New Galapagos Asset Added to the Pipeline; Gilead’s Q4 2022 Earnings Call Summary; Gracell Reports FDA IND Clearance for GC012F in R/R MMAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 03 | 2023Increased Sales for Abecma and Breyanzi; BMS to Ramp Up Manufacturing Capacity in 2023; No Clinical or Regulatory Updates; BMS Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 02 | 2023Kymriah’s Sales Remain Flat; YTB323 to Be Evaluated in 1L HR LBCL; No Updates for PHE885; Novartis Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Feb 01 | 2023Thoughts on Carvykti’s CARTITUDE-4 Meeting Its Primary Endpoint in 2 - 4L MMAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi Meets Primary Endpoint in Pivotal Trial for R/R CLLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 27 | 2023Carvykti’s CARTITUDE-4 Met its Primary Endpoint in r/r MMAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi 2L LBCL Absent from Third Consecutive Meeting; January’s CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics Jan 25 | 2023Carvykti’s Revenue Remains Flat; CARTITUDE-4 Readout Expected in 2023; JNJ Q4 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 23 | 2023Breyanzi Absent from January’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, TCR Jan 20 | 2023Thoughts on AstraZeneca's Cell Therapy PipelineAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jan 13 | 2023JPM 2023 Analysis Day 4: Autolus and Caribou BiosciencesAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Jan 12 | 2023JPM 2023 Analysis Day 3: Century Tx, Atara Bio, and PrecigenAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 11 | 2023Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSKAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 10 | 2023JPM 2023 Analysis Day 1: BMS, Novartis, JNJ, and GileadAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.